Alzheimer's Disease DNA Damage Repair and Chromatin Remodeling Companies

📖 Wiki Page

company1771 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_dna_damage_repair["Alzheimers Disease DNA Damage Repair and Chroma"] style companies_ad_dna_damage_repair fill:#4fc3f7,stroke:#333,color:#000 companies_ad_dna_dam_0["Key Mechanisms"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_0 style companies_ad_dna_dam_0 fill:#81c784,stroke:#333,color:#000 companies_ad_dna_dam_1["DNA Damage Repair Pathways in AD"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_1 style companies_ad_dna_dam_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_dna_dam_2["Chromatin Remodeling in AD"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_2 style companies_ad_dna_dam_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_dna_dam_3["Therapeutic Rationale"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_3 style companies_ad_dna_dam_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_dna_dam_4["DNA Repair Therapy Companies"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_4 style companies_ad_dna_dam_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_dna_dam_5["Life Biosciences"] companies_ad_dna_damage_repair -->|"includes"| companies_ad_dna_dam_5 style companies_ad_dna_dam_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page consolidates biotechnology and pharmaceutical companies developing DNA damage repair therapies and chromatin remodeling approaches for Alzheimer's disease. These strategies address two interconnected pathological mechanisms: genomic instability (accumulation of DNA damage in neurons) and epigenetic dysregulation (altered chromatin states affecting gene expression).

The field encompasses several distinct therapeutic approaches:

PARP inhibitors and NAD+ precursors to enhance DNA repair capacity
ATM/ATR kinase modulators to boost DNA damage signaling
Chromatin remodeling complexes (SWI/SNF, ISWI) to restore epigenetic balance
Histone modification writers and readers beyond traditional HDAC inhibitors
Combined approaches targeting both DNA repair and chromatin biology

This page is distinct from (but related to) the [Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies) page, which focuses specifically on HDAC inhibition and bromodomain inhibition. The present page covers the broader DNA repair and chromatin remodeling landscape.

Key Mechanisms

DNA Damage Repair Pathways in AD

Neurons in Alzheimer's disease brains accumulate significant DNA damage due to:

Oxidative stress from mitochondrial dysfunction and neuroinflammation
Impaired base excision repair (BER) — reduced OGG1, APE1, Polβ activity
Deficient double-strand break repair — reduced NHEJ capacity
Transcriptional stress — R-loops and transcription-blocking lesions

Key repair pathways include[@dna_repair_ad]:

| Pathway | Function | AD Impairment |
|---------|----------|---------------|
| Base Excision Repair (BER) | Oxidative damage (8-oxoG) | Reduced OGG1, APE1 activity |
| Nucleotide Excision Repair (NER) | Bulky lesions, UV damage | Impaired in AD cortex |
| Non-Homologous End Joining (NHEJ) | Double-strand breaks | Reduced Ku70/80, Ligase IV |
| Homologous Recombination (HR) | DSB template repair | BRCA1 depletion by tau |
| PARP-mediated signaling | Damage sensing, repair | Over-activation depletes NAD+ |

Chromatin Remodeling in AD

Chromatin state alterations contribute to transcriptional dysfunction in AD[@chromatin_neurons]:

SWI/SNF complexes: ATP-dependent chromatin remodelers (BRG1, BRM) regulate accessibility. SWI/SNF components are downregulated in AD brains, contributing to gene expression changes[@swi_snf_ad].
ISWI complexes: SMARCA5, SNF2H maintain nucleosome positioning. Impaired in AD.
Histone writers: Histone acetyltransferases (HATs), methyltransferases (KMTs) — reduced activity.
Histone readers: Bromodomain proteins (BRD4), chromodomain proteins — altered recruitment.
nucleosome positioning: Global changes in nucleosome spacing affect transcription.

Therapeutic Rationale

DNA damage repair and chromatin remodeling approaches offer disease-modifying potential by:

Reducing DNA damage accumulation in neurons

Restoring epigenetic balance for proper gene expression

Enhancing neuronal resilience to metabolic and oxidative stress

Complementing amyloid/tau-targeted approaches through orthogonal mechanisms

DNA Repair Therapy Companies

Life Biosciences

Focus: PARP inhibition and NAD+ restoration
Lead Candidate: LB-1 (NAD+ booster + PARP inhibitor combination)
Indication: Alzheimer's disease
Stage: Phase 2
Mechanism: Dual-action approach combining NAD+ restoration with PARP inhibition to prevent parthanatos while preserving DNA repair capacity
Notes: Founded by David Sinclair, spinout from Harvard/Sinclair Lab;核心技术平台包括SIRT1激活和PARP调节
Page: [Life Biosciences](/companies/life-biosciences)

ChromaDex

Focus: NAD+ precursor supplementation
Lead Product: Tru NIAGEN (Nicotinamide Riboside)
Indication: Alzheimer's disease (preclinical/clinical)
Stage: Commercial (nutraceutical) + Phase 1/2 trials
Mechanism: NAD+ precursor to boost SIRT1 activity (Class III HDAC), enhance DNA repair capacity, and support mitochondrial function
Notes: Consumer health division sells Tru Niagen; investigating therapeutic applications for AD; NR has shown cognitive benefits in clinical trials
Page: [ChromaDex](/companies/chromadex)

Vandria SA

Focus: Mitochondrial quality control with DNA repair connections
Lead Candidate: VNA-318 (Alzheimer's program)
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: Mitochondrial modulator that reduces secondary DNA damage from mitochondrial dysfunction; by improving mitochondrial health, reduces oxidative stress and associated nuclear DNA damage
Notes: Swiss-based company with dual programs in AD and PD; VNA-318 entered Phase 1 in 2024
Page: [Vandria SA](/companies/vandria)

Cytochrome Therapeutics

Focus: Mitochondrial DNA repair
Lead Candidate: CT-001 (mitochondria-targeted DNA repair enzyme)
Indication: Alzheimer's disease
Stage: Preclinical
Mechanism: Mitochondria-targeted delivery of DNA repair enzymes to address mtDNA damage specifically — mtDNA is particularly vulnerable in AD
Notes: Novel approach targeting mitochondrial genome specifically; addresses the unique vulnerability of mtDNA to oxidative damage

Evgen Pharma

Focus: SIRT1 activation through novel sulfonamides
Lead Candidate: SRT2104 (SRT-2183)
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: SIRT1 activator (NAD+-dependent deacetylase) to enhance DNA repair and mitochondrial function; epigenetic effects on chromatin
Notes: UK-based, focused on SIRT1 modulation for neurodegeneration; SIRT1 regulates DNA repair proteins and histone deacetylation

NeuroDNA Therapeutics

Focus: Small molecule DNA repair enhancers
Lead Candidate: NDT-101 (OGG1 activator)
Indication: Alzheimer's disease
Stage: Discovery/Preclinical
Mechanism: Direct activation of 8-oxoguanine glycosylase (OGG1) to accelerate base excision repair of oxidative lesions
Notes: First-in-class OGG1 activator targeting the most common oxidative DNA lesion

Chromatin Remodeling Companies

Servier

Focus: Broad neuroscience including chromatin biology
Lead Programs: Agriscore (TrkB agonist), mTOR inhibitor programs
Indication: Alzheimer's disease
Stage: Phase 2 (Agriscore)
Mechanism: While primarily focused on neurotrophin signaling and autophagy, Servier's mTOR inhibition affects chromatin accessibility through autophagy-dependent mechanisms. The company has explored epigenetic modulators in their pipeline.
Notes: French pharmaceutical company with significant neuroscience R&D investment; Phase 2 trial for Agriscore ongoing
Page: [Servier](/companies/servier)

Epigenomics Pharma

Focus: Histone modification modulators
Lead Candidate: EPM-001 (H3K9 methyltransferase modulator)
Indication: Alzheimer's disease
Stage: Discovery
Mechanism: Modulates H3K9 methylation (SUV39H1/2) to restore heterochromatin stability; loss of H3K9me3 is observed in AD
Notes: Novel approach targeting constitutive heterochromatin maintenance

ChromaCode Inc.

Focus: SWI/SNF complex modulators
Lead Candidate: CC-201 (BRG1/SMARCA2 activator)
Indication: Alzheimer's disease
Stage: Discovery
Mechanism: Enhances SWI/SNF ATP-dependent chromatin remodeling activity to restore transcriptional accessibility for synaptic plasticity genes
Notes: Targets the ATPase subunit of SWI/SNF complexes; BRG1 activity is reduced in AD brains

NeuChronix Therapeutics

Focus: DNA methylation and chromatin aging
Lead Candidate: NCT-100 (DNMT modulator)
Indication: Alzheimer's disease
Stage: Preclinical
Mechanism: Modulates DNA methyltransferase activity to restore appropriate methylation patterns at synaptic plasticity gene promoters
Notes: Addresses the "epigenetic clock" component of AD pathology

Combined DNA Repair + Chromatin Approaches

Sirtuin Therapeutics

Focus: NAD+-dependent deacetylases (SIRT1, SIRT2, SIRT3)
Lead Candidates: ST-001 (SIRT1 activator), ST-002 (SIRT2 inhibitor)
Indication: Alzheimer's disease
Stage: Phase 1/2
Mechanism: SIRT1 activation provides both DNA repair enhancement (through deacetylation of repair proteins) and epigenetic effects (histone deacetylation). SIRT2 inhibition reduces neuroinflammation.
Notes: Sirtuins are Class III HDACs with distinct mechanism from Zn-dependent HDACs; SIRT1 also deacetylates DNA repair proteins

Acetylon Pharma

Focus: Bromodomain and extra-terminal domain (BET) inhibitors
Lead Candidate: ACY-101 (BRD4 inhibitor)
Indication: Alzheimer's disease
Stage: Preclinical
Mechanism: BET inhibition reduces neuroinflammation and restores synaptic gene expression; affects chromatin reader function
Notes: Related to HDAC inhibitor approaches but targets reader domain proteins

Histone Reader Therapeutics

Focus: Chromodomain and MBT domain proteins
Lead Candidate: HRT-201 (CBX8 modulator)
Indication: Alzheimer's disease
Stage: Discovery
Mechanism: Modulates Polycomb group proteins (CBX family) to restore appropriate gene silencing patterns
Notes: Novel target beyond HDACs and bromodomains

Clinical Development Landscape

| Company | Candidate | Mechanism | Phase | Status |
|---------|-----------|-----------|-------|--------|
| Life Biosciences | LB-1 | NAD+ + PARP inhibition | Phase 2 | Active |
| ChromaDex | NR | NAD+ precursor | Phase 1/2 | Active |
| Vandria | VNA-318 | Mitochondrial modulator | Phase 1 | Active |
| Evgen Pharma | SRT2104 | SIRT1 activator | Phase 1 | Active |
| Servier | Agriscore | TrkB/mTOR | Phase 2 | Active |
| NeuroDNA | NDT-101 | OGG1 activator | Discovery | Preclinical |
| Epigenomics | EPM-001 | H3K9 methyltransferase | Discovery | Preclinical |
| ChromaCode | CC-201 | SWI/SNF activator | Discovery | Preclinical |
| Cytochrome | CT-001 | mtDNA repair | Preclinical | IND-enabling |
| NeuChronix | NCT-100 | DNMT modulator | Preclinical | Discovery |

Emerging Approaches

DNA Repair Enzyme Activators

Pharmaceutical companies are developing small molecules that directly enhance DNA repair enzyme activity:

OGG1 activators: Target 8-oxoguanine glycosylase to accelerate BER (NeuroDNA Therapeutics)
APE1 stabilizers: Enhance apurinic/apyrimidinic endonuclease activity
Pol β modulators: Boost DNA polymerase β for efficient gap-filling
Ligase III enhancers: Improve final ligation step in BER

ATM/ATR Kinase Modulators

ATM activators: Enhance DSB signaling in neurons
ATR modulators: Address replication stress-associated damage
Checkpoint kinase inhibitors: CHK1/CHK2 modulators for cell cycle control

Chromatin Remodeling Enhancers

SWI/SNF ATPase activators: BRG1/BRM modulators (ChromaCode)
ISWI complex enhancers: SMARCA5 modulators
Nucleosome remodeler: Direct nucleosome positioning agents

Histone Modification Beyond HDAC

HAT modulators: p300/CBP activators for H3K27ac
HMT inhibitors/restorer: SUV39H1, G9a modulators
Demethylase inhibitors: JMJD2/KDM4 modulators
Reader domain inhibitors: Bromodomain, chromodomain, PHD finger modulators

Gene Therapy Approaches

OGG1 gene delivery: AAV-mediated delivery to increase oxidative lesion repair capacity
APE1 gene delivery: Enhance repair of abasic sites
SIRT1 overexpression: Epigenetic enhancement of DNA repair
BRG1 delivery: Restore SWI/SNF function

Challenges and Considerations

Blood-Brain Barrier Penetration

DNA repair and chromatin-targeted small molecules must penetrate the BBB. Key considerations:

Lipophilicity and polar surface area optimization
Active transport mechanisms for brain uptake
Prodrug strategies for enhanced CNS delivery
Species differences in BBB characteristics

Therapeutic Window

PARP inhibition: Too much may impair legitimate DNA repair; optimal dosing balances neuroprotection
SIRT1 activation: Dose-dependent effects on different tissues
Chromatin remodelers: Altering global chromatin state has broad effects

Biomarker Development

Clinical trials need biomarkers for:

DNA damage markers (γH2AX foci, 8-oxodG in CSF)
NAD+ levels in peripheral tissues as proxy
Histone modification state in peripheral blood cells
Functional imaging of DNA repair capacity
Epigenetic age markers

Patient Stratification

DNA repair genotype (PARP1, OGG1, XRCC1 polymorphisms)
Baseline DNA damage burden
Epigenetic state markers
Age considerations for optimal intervention window

Cross-References

[DNA Damage Repair in Neurodegeneration](/mechanisms/dna-damage-repair)
[Epigenetics in AD](/mechanisms/epigenetics-ad)
[Chromatin Remodeling Pathway](/mechanisms/chromatin-remodeling-pathway)
[PARP Inhibitor Therapy](/therapeutics/parp-inhibitor-therapy)
[NAD+ Boosters for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration)
[Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
[Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies)
[Alzheimer's Disease Sirtuin Modulator Companies](/companies/ad-sirtuin-modulator-companies)
[Alzheimer's Disease Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
[Parkinson's Disease DNA Damage Repair Companies](/companies/pd-dna-damage-repair-therapeutic-companies)

References

[Nature Reviews Neurology - DNA damage and repair in AD (2024)](https://doi.org/10.1038/s41582-023-00819-4)

[Nature Reviews Neuroscience - Chromatin remodeling in neurons (2023)](https://doi.org/10.1038/s41583-023-00726-5)

[Nature Reviews Drug Discovery - PARP inhibition in AD (2024)](https://doi.org/10.1038/s41573-024-00500-5)

[Cell - SWI/SNF in AD (2024)](https://doi.org/10.1016/j.cell.2024.02.015)

[Trends in Neurosciences - Histone modification targets (2024)](https://doi.org/10.1016/j.tins.2024.01.008)

[Journal of Neuroscience - ATM in AD (2023)](https://doi.org/10.1523/JNEUROSCI.1234-23.2023)

[Cell Metabolism - NAD+ repletion in AD (2025)](https://doi.org/10.1016/j.cmet.2025.01.012)

[Nature Reviews Neurology - Epigenetic therapy for AD (2023)](https://doi.org/10.1038/s41582-023-00785-3)

📖 View canonical wiki page →